Solifenacin

• UNSPSC Description:

  Solifenacin (YM905 free base) is a novel muscarinic receptor antagonist with pKis of 7.6, 6.9 and 8.0 for M1, M2 and M3 receptors, respectively.

• Target Antigen:

  mAChR

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein;Neuronal Signaling

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Neurological Disease; Cancer

• Assay Protocol:

  https://www.medchemexpress.com/Solifenacin.html

• Purity:

  99.83

• Solubility:

  DMSO : ≥ 50 mg/mL|H2O : < 0.1 mg/mL (ultrasonic)

• Smiles:

  O=C(O[C@@]1([H])C[N@]2CC[C@@H]1CC2)N3CCC4=CC=CC=C4[C@@H]3C5=CC=CC=C5

• Molecular Weight:

  362.46

• References & Citations:

  [1]Ikeda K, et al. M(3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. Naunyn Schmiedebergs Arch Pharmacol. 2002 Aug;366(2):97-103.|[2]Suzuki M, et al. Effects of solifenacin succinate (YM905) on detrusor overactivity in conscious cerebral infarctedrats. Eur J Pharmacol. 2005 Apr 4;512(1):61-6.Int J Nanomedicine. 2024 Aug 15:19:8353-8371.|J Chem Neuroanat. 2023 Dec 18:102375.|Neurourol Urodyn. 2017 Apr;36(4):1026-1033.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  Launched

• CAS Number:

  242478-37-1